Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.
Identifieur interne : 000351 ( PubMed/Checkpoint ); précédent : 000350; suivant : 000352Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.
Auteurs : S. Bantia [États-Unis] ; A A Ghate ; S L Ananth ; Y S Babu ; G M Air ; G M WalshSource :
- Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 1998.
Descripteurs français
- KwdFr :
- Agents colorants, Animaux, Antienzymes (pharmacologie), Benzoates (pharmacologie), Chiens, Humains, Hémagglutinines (génétique), Lignée cellulaire, Mutation (), Méthode des plages virales, Phénotype, Réplication virale (), Résistance microbienne aux médicaments, Sels de tétrazolium, Sialidase (antagonistes et inhibiteurs), Sialidase (génétique), Thiazoles, Virus de la grippe A (), Virus de la grippe A (enzymologie), Virus de la grippe A (génétique), Érythrocytes ().
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- enzymologie : Virus de la grippe A.
- génétique : Hémagglutinines, Sialidase, Virus de la grippe A.
- pharmacologie : Antienzymes, Benzoates.
- Agents colorants, Animaux, Chiens, Humains, Lignée cellulaire, Mutation, Méthode des plages virales, Phénotype, Réplication virale, Résistance microbienne aux médicaments, Sels de tétrazolium, Thiazoles, Virus de la grippe A, Érythrocytes.
English descriptors
- KwdEn :
- Animals, Benzoates (pharmacology), Cell Line, Coloring Agents, Dogs, Drug Resistance, Microbial, Enzyme Inhibitors (pharmacology), Erythrocytes (drug effects), Hemagglutinins (genetics), Humans, Influenza A virus (drug effects), Influenza A virus (enzymology), Influenza A virus (genetics), Mutation (drug effects), Neuraminidase (antagonists & inhibitors), Neuraminidase (genetics), Phenotype, Tetrazolium Salts, Thiazoles, Viral Plaque Assay, Virus Replication (drug effects).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , genetics : Hemagglutinins, Neuraminidase.
- chemical , pharmacology : Benzoates, Enzyme Inhibitors.
- drug effects : Erythrocytes, Influenza A virus, Mutation, Virus Replication.
- enzymology : Influenza A virus.
- genetics : Influenza A virus.
- Animals, Cell Line, Coloring Agents, Dogs, Drug Resistance, Microbial, Humans, Phenotype, Tetrazolium Salts, Thiazoles, Viral Plaque Assay.
Abstract
Influenza neuraminidase (NA) plays an important role in viral replication, and characterization of viruses resistant to NA inhibitors will help elucidate the role of active-site residues. This information will assist in designing better inhibitors targeted to essential active-site residues that cannot generate drug-resistant mutations. In the present study we used the benzoic acid-based inhibitor BCX-140 to select and characterize resistant viruses. BCX-140 binds to the NA active site in an orientation that is opposite that of a sialic acid-based compound, 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (GANA). Thus, the guanidino group of BCX-140 binds to Glu-276, whereas in GANA the guanidino group binds to Glu-119. We passaged influenza A/Singapore/1/57 (H2N2) in Madin-Darby canine kidney cells in the presence of BCX-140, and virus resistant to this inhibitor was selected after six passages. The NA of this mutant was still sensitive to inhibition by BCX-140. However, the mutant virus was resistant to BCX-140 in plaque and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Sequence analysis of hemagglutinin (HA) and NA genes revealed changes in both, although none were in the active site of the NA. Depending on the method of selection of the resistant virus, two types of changes associated with the sialic acid binding site were seen in the HA. One is a change in HA1 of Ala-133 to Thr, a residue close to the binding site, while the other change was Arg-132 of HA1 to Gln, which in HA1 of serotype H3 is a sialic acid contact (Asn-137). Binding studies revealed that both types of resistant viruses had reduced receptor binding affinity compared to that of the wild type. Thus, resistance to BCX-140 was generated by modifying the HA. NA active-site residue 276 may be essential for activity, and thus, it cannot be changed to generate resistance. However, drug-induced changes in the HA can result in a virus that is less dependent on NA activity for growth in cells and, hence, resistant to NA inhibitors.
PubMed: 9559786
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9559786Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.</title><author><name sortKey="Bantia, S" sort="Bantia, S" uniqKey="Bantia S" first="S" last="Bantia">S. Bantia</name><affiliation wicri:level="1"><nlm:affiliation>BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244, USA. sbantia@biocryst.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244</wicri:regionArea><wicri:noRegion>Alabama 35244</wicri:noRegion></affiliation></author><author><name sortKey="Ghate, A A" sort="Ghate, A A" uniqKey="Ghate A" first="A A" last="Ghate">A A Ghate</name></author><author><name sortKey="Ananth, S L" sort="Ananth, S L" uniqKey="Ananth S" first="S L" last="Ananth">S L Ananth</name></author><author><name sortKey="Babu, Y S" sort="Babu, Y S" uniqKey="Babu Y" first="Y S" last="Babu">Y S Babu</name></author><author><name sortKey="Air, G M" sort="Air, G M" uniqKey="Air G" first="G M" last="Air">G M Air</name></author><author><name sortKey="Walsh, G M" sort="Walsh, G M" uniqKey="Walsh G" first="G M" last="Walsh">G M Walsh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9559786</idno><idno type="pmid">9559786</idno><idno type="wicri:Area/PubMed/Corpus">000385</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000385</idno><idno type="wicri:Area/PubMed/Curation">000385</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000385</idno><idno type="wicri:Area/PubMed/Checkpoint">000351</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000351</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.</title><author><name sortKey="Bantia, S" sort="Bantia, S" uniqKey="Bantia S" first="S" last="Bantia">S. Bantia</name><affiliation wicri:level="1"><nlm:affiliation>BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244, USA. sbantia@biocryst.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244</wicri:regionArea><wicri:noRegion>Alabama 35244</wicri:noRegion></affiliation></author><author><name sortKey="Ghate, A A" sort="Ghate, A A" uniqKey="Ghate A" first="A A" last="Ghate">A A Ghate</name></author><author><name sortKey="Ananth, S L" sort="Ananth, S L" uniqKey="Ananth S" first="S L" last="Ananth">S L Ananth</name></author><author><name sortKey="Babu, Y S" sort="Babu, Y S" uniqKey="Babu Y" first="Y S" last="Babu">Y S Babu</name></author><author><name sortKey="Air, G M" sort="Air, G M" uniqKey="Air G" first="G M" last="Air">G M Air</name></author><author><name sortKey="Walsh, G M" sort="Walsh, G M" uniqKey="Walsh G" first="G M" last="Walsh">G M Walsh</name></author></analytic><series><title level="j">Antimicrobial agents and chemotherapy</title><idno type="ISSN">0066-4804</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Benzoates (pharmacology)</term><term>Cell Line</term><term>Coloring Agents</term><term>Dogs</term><term>Drug Resistance, Microbial</term><term>Enzyme Inhibitors (pharmacology)</term><term>Erythrocytes (drug effects)</term><term>Hemagglutinins (genetics)</term><term>Humans</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (enzymology)</term><term>Influenza A virus (genetics)</term><term>Mutation (drug effects)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (genetics)</term><term>Phenotype</term><term>Tetrazolium Salts</term><term>Thiazoles</term><term>Viral Plaque Assay</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents colorants</term><term>Animaux</term><term>Antienzymes (pharmacologie)</term><term>Benzoates (pharmacologie)</term><term>Chiens</term><term>Humains</term><term>Hémagglutinines (génétique)</term><term>Lignée cellulaire</term><term>Mutation ()</term><term>Méthode des plages virales</term><term>Phénotype</term><term>Réplication virale ()</term><term>Résistance microbienne aux médicaments</term><term>Sels de tétrazolium</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sialidase (génétique)</term><term>Thiazoles</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (enzymologie)</term><term>Virus de la grippe A (génétique)</term><term>Érythrocytes ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinins</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Benzoates</term><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Erythrocytes</term><term>Influenza A virus</term><term>Mutation</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hémagglutinines</term><term>Sialidase</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term><term>Benzoates</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Coloring Agents</term><term>Dogs</term><term>Drug Resistance, Microbial</term><term>Humans</term><term>Phenotype</term><term>Tetrazolium Salts</term><term>Thiazoles</term><term>Viral Plaque Assay</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Agents colorants</term><term>Animaux</term><term>Chiens</term><term>Humains</term><term>Lignée cellulaire</term><term>Mutation</term><term>Méthode des plages virales</term><term>Phénotype</term><term>Réplication virale</term><term>Résistance microbienne aux médicaments</term><term>Sels de tétrazolium</term><term>Thiazoles</term><term>Virus de la grippe A</term><term>Érythrocytes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza neuraminidase (NA) plays an important role in viral replication, and characterization of viruses resistant to NA inhibitors will help elucidate the role of active-site residues. This information will assist in designing better inhibitors targeted to essential active-site residues that cannot generate drug-resistant mutations. In the present study we used the benzoic acid-based inhibitor BCX-140 to select and characterize resistant viruses. BCX-140 binds to the NA active site in an orientation that is opposite that of a sialic acid-based compound, 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (GANA). Thus, the guanidino group of BCX-140 binds to Glu-276, whereas in GANA the guanidino group binds to Glu-119. We passaged influenza A/Singapore/1/57 (H2N2) in Madin-Darby canine kidney cells in the presence of BCX-140, and virus resistant to this inhibitor was selected after six passages. The NA of this mutant was still sensitive to inhibition by BCX-140. However, the mutant virus was resistant to BCX-140 in plaque and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Sequence analysis of hemagglutinin (HA) and NA genes revealed changes in both, although none were in the active site of the NA. Depending on the method of selection of the resistant virus, two types of changes associated with the sialic acid binding site were seen in the HA. One is a change in HA1 of Ala-133 to Thr, a residue close to the binding site, while the other change was Arg-132 of HA1 to Gln, which in HA1 of serotype H3 is a sialic acid contact (Asn-137). Binding studies revealed that both types of resistant viruses had reduced receptor binding affinity compared to that of the wild type. Thus, resistance to BCX-140 was generated by modifying the HA. NA active-site residue 276 may be essential for activity, and thus, it cannot be changed to generate resistance. However, drug-induced changes in the HA can result in a virus that is less dependent on NA activity for growth in cells and, hence, resistant to NA inhibitors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9559786</PMID><DateCompleted><Year>1998</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0066-4804</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>1998</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation></Journal><ArticleTitle>Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.</ArticleTitle><Pagination><MedlinePgn>801-7</MedlinePgn></Pagination><Abstract><AbstractText>Influenza neuraminidase (NA) plays an important role in viral replication, and characterization of viruses resistant to NA inhibitors will help elucidate the role of active-site residues. This information will assist in designing better inhibitors targeted to essential active-site residues that cannot generate drug-resistant mutations. In the present study we used the benzoic acid-based inhibitor BCX-140 to select and characterize resistant viruses. BCX-140 binds to the NA active site in an orientation that is opposite that of a sialic acid-based compound, 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (GANA). Thus, the guanidino group of BCX-140 binds to Glu-276, whereas in GANA the guanidino group binds to Glu-119. We passaged influenza A/Singapore/1/57 (H2N2) in Madin-Darby canine kidney cells in the presence of BCX-140, and virus resistant to this inhibitor was selected after six passages. The NA of this mutant was still sensitive to inhibition by BCX-140. However, the mutant virus was resistant to BCX-140 in plaque and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Sequence analysis of hemagglutinin (HA) and NA genes revealed changes in both, although none were in the active site of the NA. Depending on the method of selection of the resistant virus, two types of changes associated with the sialic acid binding site were seen in the HA. One is a change in HA1 of Ala-133 to Thr, a residue close to the binding site, while the other change was Arg-132 of HA1 to Gln, which in HA1 of serotype H3 is a sialic acid contact (Asn-137). Binding studies revealed that both types of resistant viruses had reduced receptor binding affinity compared to that of the wild type. Thus, resistance to BCX-140 was generated by modifying the HA. NA active-site residue 276 may be essential for activity, and thus, it cannot be changed to generate resistance. However, drug-induced changes in the HA can result in a virus that is less dependent on NA activity for growth in cells and, hence, resistant to NA inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bantia</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244, USA. sbantia@biocryst.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghate</LastName><ForeName>A A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Ananth</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Y S</ForeName><Initials>YS</Initials></Author><Author ValidYN="Y"><LastName>Air</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI018203</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI018203</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI-18203</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C112527">BCX 140</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001565">Benzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004396">Coloring Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006388">Hemagglutinins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013778">Tetrazolium Salts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EUY85H477I</RegistryNumber><NameOfSubstance UI="C022616">thiazolyl blue</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001565" MajorTopicYN="N">Benzoates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004396" MajorTopicYN="N">Coloring Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004352" MajorTopicYN="N">Drug Resistance, Microbial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006388" MajorTopicYN="N">Hemagglutinins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013778" MajorTopicYN="N">Tetrazolium Salts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>4</Month><Day>29</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>4</Month><Day>29</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9559786</ArticleId><ArticleId IdType="pmc">PMC105545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Virology. 1995 Dec 20;214(2):642-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8553569</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteins. 1995 Oct;23(2):264-77</Citation><ArticleIdList><ArticleId IdType="pubmed">8592707</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1996 Mar;70(3):1818-27</Citation><ArticleIdList><ArticleId IdType="pubmed">8627706</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1996 Jan;40(1):40-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8787876</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1974 Oct;61(2):397-410</Citation><ArticleIdList><ArticleId IdType="pubmed">4472498</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 1979 Apr 15;94(2):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">464297</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1980 May;17(5):865-70</Citation><ArticleIdList><ArticleId IdType="pubmed">7396473</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1981 Jan 29;289(5796):366-73</Citation><ArticleIdList><ArticleId IdType="pubmed">7464906</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1983 May 5-11;303(5912):41-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6188957</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1985 Sep;145(2):237-48</Citation><ArticleIdList><ArticleId IdType="pubmed">2411049</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1989 Jun;159(6):1050-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2723453</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1991 Nov 1;134(9):988-97</Citation><ArticleIdList><ArticleId IdType="pubmed">1951297</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1991 Sep;35(9):1741-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1952841</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 1992 Sep;19(3):207-17</Citation><ArticleIdList><ArticleId IdType="pubmed">1444327</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1992 Dec;191(2):541-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1448912</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1993 Jun 3;363(6428):418-23</Citation><ArticleIdList><ArticleId IdType="pubmed">8502295</ArticleId></ArticleIdList></Reference><Reference><Citation>Glycoconj J. 1993 Feb;10(1):40-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8358225</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1993 Jul;37(7):1473-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8363379</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 1994 Aug;24(4):351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7993078</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 Feb;69(2):1099-106</Citation><ArticleIdList><ArticleId IdType="pubmed">7815489</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Sci. 1994 Oct;3(10):1687-96</Citation><ArticleIdList><ArticleId IdType="pubmed">7849585</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 1995 Aug 18;38(17):3217-25</Citation><ArticleIdList><ArticleId IdType="pubmed">7650674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Air, G M" sort="Air, G M" uniqKey="Air G" first="G M" last="Air">G M Air</name><name sortKey="Ananth, S L" sort="Ananth, S L" uniqKey="Ananth S" first="S L" last="Ananth">S L Ananth</name><name sortKey="Babu, Y S" sort="Babu, Y S" uniqKey="Babu Y" first="Y S" last="Babu">Y S Babu</name><name sortKey="Ghate, A A" sort="Ghate, A A" uniqKey="Ghate A" first="A A" last="Ghate">A A Ghate</name><name sortKey="Walsh, G M" sort="Walsh, G M" uniqKey="Walsh G" first="G M" last="Walsh">G M Walsh</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Bantia, S" sort="Bantia, S" uniqKey="Bantia S" first="S" last="Bantia">S. Bantia</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000351 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000351 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9559786
|texte= Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX-140.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9559786" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |